Selected studies in the last 5 years evaluating the outcome of peripheral T-cell lymphoma (PTCL) patients who have received high dose chemotherapy and autologous (auto) or allogeneic (allo) stem cell transplant in first remission or with relapsed refractory disease.
| Study . | Total No. Pts . | PTCL Subtype (n) . | First Remission or Relapsed/Refractory (n) . | EFS/PFS . | OS . | Comments . |
|---|---|---|---|---|---|---|
| Abbreviations: AILT, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma kinase; ALCL, anaplastic large cell lymphoma (ALK positive (+) and negative (−); CUTALCL, cutaneous ALCL; EFS, event-free survival; ETTL, enteropathy-associated T-cell lymphoma; PFS, progression-free survival; OS, overall survival; PR, partial remission; PTCLUS, peripheral T-cell lymphoma, unspecified; Auto, high-dose chemotherapy and autologous stem cell transplant; allo, allogeneic transplant; RIC, reduced intensity conditioning | ||||||
| Rodriguez38 | 115 | PTCLUS (80) | First remission (37) | 79% (5 y) | 80 % (5 y) | ALK status unknown; median age 31 for primary transplant |
| ALCL (25) | Auto | |||||
| AILT (6) | ||||||
| Other (2) | Relapsed/refractory (78) | 79% (5 y) | 80% (5 y) | No patient salvaged with refractory disease | ||
| Auto | 39% (5 y) | 45% (5 y) | ||||
| Jagasia43 | 28 | PTCLUS (6) | Relapsed/refractory | 50% (3 y) | 43% (6 y) | Outcome analyses combined auto and allo transplants superior outcome to other PTCLs and DLBCL |
| ALCL (11) | Auto (23) | |||||
| Allo (5) | Non-ALCL 38% (3 y) | Non-ALCL 47% (3 y) | ||||
| ALK positive (7) | ||||||
| ALK negative (4) | ||||||
| CUTALCL (5) | ||||||
| AILT (3) | ALK ALCL | ALK+ ALCL 100% (3 y) | ALK+ ALCL 100% (3 y) | |||
| NK/T (3) | ALK− ALCL 0% (3 y) | ALK− ALCL 50% (3 y) | ||||
| Blystad39 | 40 | PTCLUS(20) | First remission (17) | 48% (3 y) | 58% (3 y) | Outcome analyses combined first remission and relapsed groups ALK status unknown |
| ALCL (14) | Auto | |||||
| AILT (2) | non-ALCL 44% (3 y) | |||||
| ETTL (2) | Relapsed (23) | ALCL 79% (3 y) | ||||
| NK/T (2) | Auto | |||||
| Song44 | 36 | PTCLUS (20) | Relapsed/refractory | 37% (3 y) | 48% (3 y) | ALCL (ALK status unknown) xxx to improve outcome compared with PTCLUS and DLBCL |
| ALCL (9) | Auto | |||||
| AILT (2) | PTCLUS 23% (3 y) | PTCLUS 35% (3 y) | ||||
| NK/T (4) | ||||||
| ETTL (1) | ALCL 67% (3 y) | ALCL 78% (3 y) | ||||
| Corradini47 | 17 | PTCLUS (9) | Relapsed/refractory | 64% (3 y) | 81% (3 y) | Many had late relapses |
| ALK− ALCL (4) | RIC Allo | |||||
| AILT (4) | Unknown whether primary CUTALCL were included | |||||
| Study . | Total No. Pts . | PTCL Subtype (n) . | First Remission or Relapsed/Refractory (n) . | EFS/PFS . | OS . | Comments . |
|---|---|---|---|---|---|---|
| Abbreviations: AILT, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma kinase; ALCL, anaplastic large cell lymphoma (ALK positive (+) and negative (−); CUTALCL, cutaneous ALCL; EFS, event-free survival; ETTL, enteropathy-associated T-cell lymphoma; PFS, progression-free survival; OS, overall survival; PR, partial remission; PTCLUS, peripheral T-cell lymphoma, unspecified; Auto, high-dose chemotherapy and autologous stem cell transplant; allo, allogeneic transplant; RIC, reduced intensity conditioning | ||||||
| Rodriguez38 | 115 | PTCLUS (80) | First remission (37) | 79% (5 y) | 80 % (5 y) | ALK status unknown; median age 31 for primary transplant |
| ALCL (25) | Auto | |||||
| AILT (6) | ||||||
| Other (2) | Relapsed/refractory (78) | 79% (5 y) | 80% (5 y) | No patient salvaged with refractory disease | ||
| Auto | 39% (5 y) | 45% (5 y) | ||||
| Jagasia43 | 28 | PTCLUS (6) | Relapsed/refractory | 50% (3 y) | 43% (6 y) | Outcome analyses combined auto and allo transplants superior outcome to other PTCLs and DLBCL |
| ALCL (11) | Auto (23) | |||||
| Allo (5) | Non-ALCL 38% (3 y) | Non-ALCL 47% (3 y) | ||||
| ALK positive (7) | ||||||
| ALK negative (4) | ||||||
| CUTALCL (5) | ||||||
| AILT (3) | ALK ALCL | ALK+ ALCL 100% (3 y) | ALK+ ALCL 100% (3 y) | |||
| NK/T (3) | ALK− ALCL 0% (3 y) | ALK− ALCL 50% (3 y) | ||||
| Blystad39 | 40 | PTCLUS(20) | First remission (17) | 48% (3 y) | 58% (3 y) | Outcome analyses combined first remission and relapsed groups ALK status unknown |
| ALCL (14) | Auto | |||||
| AILT (2) | non-ALCL 44% (3 y) | |||||
| ETTL (2) | Relapsed (23) | ALCL 79% (3 y) | ||||
| NK/T (2) | Auto | |||||
| Song44 | 36 | PTCLUS (20) | Relapsed/refractory | 37% (3 y) | 48% (3 y) | ALCL (ALK status unknown) xxx to improve outcome compared with PTCLUS and DLBCL |
| ALCL (9) | Auto | |||||
| AILT (2) | PTCLUS 23% (3 y) | PTCLUS 35% (3 y) | ||||
| NK/T (4) | ||||||
| ETTL (1) | ALCL 67% (3 y) | ALCL 78% (3 y) | ||||
| Corradini47 | 17 | PTCLUS (9) | Relapsed/refractory | 64% (3 y) | 81% (3 y) | Many had late relapses |
| ALK− ALCL (4) | RIC Allo | |||||
| AILT (4) | Unknown whether primary CUTALCL were included | |||||